|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
The upregulation of karyopherin α 2 (KPNA2) and chromosome segregation 1‑like (CSE1L) in colorectal carcinoma, in addition to downregulation of chloride channel accessory 1 (CLCA1), fatty acid binding protein 1 (FABP1), sodium channel, voltage gated, type VII α subunit (SCN7A) and solute carrier family 26 (anion exchanger), member 3 (SLC26A3) was confirmed.
|
27121919 |
2016 |
|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
In conclusion, CLCA1 may contribute to promoting spontaneous differentiation and reducing proliferation of Caco-2 cells and may be a target of NaBT-induced inhibition of proliferation and therefore a potential diagnostic marker for CRC prognosis.
|
23593331 |
2013 |
|
Colorectal Carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our results suggest that CLCA1 could specify a new tumor suppressor and that, as in breast cancer, CLCA2 may function as a tumor suppressor in colorectal cancer.
|
11445004 |
2001 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
CLCA1 expression was denoted as positive in 90 tumors (64.3%), with positive staining being limited to the tumor cells.
|
30419838 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
<b>Results:</b> In validation cohort, high expression of CLCA1 was significantly associated with higher pre-treatment tumor nodal stages (P=0.032), vascular invasion (P=0.028), and inferior tumor regression grade (P=0.042).
|
30123054 |
2018 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
In addition, CLCA1 serum concentration and mRNA expression level in CRC tissues were inversely correlated with CRC metastasis and tumor stage.
|
28974231 |
2017 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Our results suggest that CLCA1 could specify a new tumor suppressor and that, as in breast cancer, CLCA2 may function as a tumor suppressor in colorectal cancer.
|
11445004 |
2001 |
|
Malignant Neoplasms
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The source of the data was The Cancer Genome Atlas, and it was identified that high expression levels of CLCA1 and CLCA2 were associated with a favorable overall survival (OS) time in patients with colon cancer.
|
31404307 |
2019 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In this review, the functional role of CLCA1, with a particular focus on cancer, is described.
|
30952704 |
2019 |
|
Chronic Obstructive Airway Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
They warrant evaluation of CLCA1 blockers as adjunctive therapy in this condition and describe a simple model to evaluate therapeutic interventions for steroid resistant mucus, a common condition in patients with chronic lung disease like asthma, chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
|
31333624 |
2019 |
|
airway disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
CLCA1 has been shown to participate in the pathogenesis of inflammatory airway diseases such as asthma.
|
30952704 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
In this review, the functional role of CLCA1, with a particular focus on cancer, is described.
|
30952704 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
AlteredExpression
|
group |
BEFREE |
The source of the data was The Cancer Genome Atlas, and it was identified that high expression levels of CLCA1 and CLCA2 were associated with a favorable overall survival (OS) time in patients with colon cancer.
|
31404307 |
2019 |
|
airway disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In addition to its ability to upregulate cytokine expression which explains previous observations in the Clca1-deficient S. aureus pneumonia mouse model, modulation of BPIFA1 expression expands the role of CLCA1 in airway disease to involvement in more complex downstream pathways, possibly including liquid homeostasis, airway protection, and antimicrobial defense.
|
29610986 |
2018 |
|
Malignant Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Moreover, inhibitor and siRNA transfection studies demonstrated an apparent effect of CLCA1 on cancer cell aggregation.
|
26004777 |
2015 |
|
airway disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
CLCA1 and TMEM16A: the link towards a potential cure for airway diseases.
|
26296094 |
2015 |
|
Primary malignant neoplasm
|
0.030 |
Biomarker
|
group |
BEFREE |
Moreover, inhibitor and siRNA transfection studies demonstrated an apparent effect of CLCA1 on cancer cell aggregation.
|
26004777 |
2015 |
|
Chronic Obstructive Airway Disease
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Using immunostaining with an anti-CLCA1 antibody, semi-quantitative image analyses of airway epithelium demonstrated significantly increased CLCA1 expression in smokers without COPD (p = 0.02) and in COPD patients (p = 0.002) compared with non-smokers.
|
22731784 |
2012 |
|
Chronic Obstructive Airway Disease
|
0.030 |
GeneticVariation
|
disease |
LHGDN |
CLCA1 gene polymorphisms in chronic obstructive pulmonary disease.
|
14985398 |
2004 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Emerging evidence suggests that CLCA1 may also be involved in the pathophysiology of colorectal, pancreatic and ovarian cancer.
|
30952704 |
2019 |
|
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
Emerging evidence suggests that CLCA1 may also be involved in the pathophysiology of colorectal, pancreatic and ovarian cancer.
|
30952704 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.020 |
Biomarker
|
disease |
BEFREE |
Emerging evidence suggests that CLCA1 may also be involved in the pathophysiology of colorectal, pancreatic and ovarian cancer.
|
30952704 |
2019 |
|
Malignant neoplasm of colon and/or rectum
|
0.020 |
Biomarker
|
disease |
BEFREE |
CLCA1 suppresses colorectal cancer aggressiveness via inhibition of the Wnt/beta-catenin signaling pathway.
|
28974231 |
2017 |
|
ovarian neoplasm
|
0.020 |
Biomarker
|
disease |
BEFREE |
Further elucidation of the role of CLCA1 in the pathogenesis of ovarian cancer is warranted.
|
26004777 |
2015 |
|
Malignant neoplasm of ovary
|
0.020 |
Biomarker
|
disease |
BEFREE |
Further elucidation of the role of CLCA1 in the pathogenesis of ovarian cancer is warranted.
|
26004777 |
2015 |